Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9073050rdf:typepubmed:Citationlld:pubmed
pubmed-article:9073050lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9073050lifeskim:mentionsumls-concept:C0019829lld:lifeskim
pubmed-article:9073050lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9073050lifeskim:mentionsumls-concept:C0442967lld:lifeskim
pubmed-article:9073050lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:9073050lifeskim:mentionsumls-concept:C0439828lld:lifeskim
pubmed-article:9073050pubmed:dateCreated1997-4-11lld:pubmed
pubmed-article:9073050pubmed:abstractTextTreatment results and prognostic variables were studied in 549 adult patients with Hodgkin's disease after first-line and salvage treatment. After first-line treatment, 479 out of 549 patients (87%) achieved complete remission (CR). During a mean observation time of 74 months, 99 patients (21%) relapsed. Sixty-nine patients (70% of relapsed patients) achieved a second CR. Variables predicting poor response (< CR) and shortened survival after first-line treatment were advanced disease, B-symptoms and age >60 years. In relapsing patients, age >60 years, relapse within 12 months and non-CR after relapse treatment predicted a poor prognosis, and none of these patients were alive after 10 years. Localized disease at diagnosis and relapse, and relapse later than 24 months predicted a good prognosis with 10-year survival after relapse of 68% and 57%, respectively. Patients with a second relapse had 5-year survival of 28% and 10-year survival of 14%. Based on the prognostic variables at first-line treatment and at relapse, selection of patients to more intensive treatment is discussed.lld:pubmed
pubmed-article:9073050pubmed:languageenglld:pubmed
pubmed-article:9073050pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9073050pubmed:citationSubsetIMlld:pubmed
pubmed-article:9073050pubmed:statusMEDLINElld:pubmed
pubmed-article:9073050pubmed:issn0284-186Xlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:HagerBBlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:NomiKKlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:AbrahamsenA...lld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:LangholmRRlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:KvaløySSlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:HannisdalEElld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:HolteHHlld:pubmed
pubmed-article:9073050pubmed:authorpubmed-author:ElgioR FRFlld:pubmed
pubmed-article:9073050pubmed:issnTypePrintlld:pubmed
pubmed-article:9073050pubmed:volume35 Suppl 8lld:pubmed
pubmed-article:9073050pubmed:ownerNLMlld:pubmed
pubmed-article:9073050pubmed:authorsCompleteYlld:pubmed
pubmed-article:9073050pubmed:pagination67-72lld:pubmed
pubmed-article:9073050pubmed:dateRevised2009-5-12lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:meshHeadingpubmed-meshheading:9073050-...lld:pubmed
pubmed-article:9073050pubmed:year1996lld:pubmed
pubmed-article:9073050pubmed:articleTitlePrognostic variables and results of salvage treatment in Hodgkin's disease.lld:pubmed
pubmed-article:9073050pubmed:affiliationDepartment of Oncology, The Norwegian Radium Hospital, Oslo.lld:pubmed
pubmed-article:9073050pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9073050pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed